首页> 外文OA文献 >PMS9 COST-EFFECTIVENESS OF ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)AND INADEQUATE RESPONSE TO METHOTREXATE (MTX) ORTUMOR NECROSIS FACTOR-ALPHA INHIBITORS (ANTI-TNFS):A CANADIAN PERSPECTIVE

【2h】

PMS9 COST-EFFECTIVENESS OF ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)AND INADEQUATE RESPONSE TO METHOTREXATE (MTX) ORTUMOR NECROSIS FACTOR-ALPHA INHIBITORS (ANTI-TNFS):A CANADIAN PERSPECTIVE

机译：活动性类风湿关节炎（RA）患者对甲氨蝶呤的PMS9成本效益以及对甲氨蝶呤（MTX）肿瘤坏死因子抑制剂（ANTI-TNFS）的反应不足：加拿大的观点

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Maier-Moldovan M; Yuan Y; Maclean R; LItalien GJ;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. [J] . Vera-Llonch M, Massarotti E, Wolfe F, The Journal of rheumatology . 2008,第9期

机译：阿巴西普在中度至重度活动性类风湿关节炎患者中的成本效益，且对肿瘤坏死因子-α拮抗剂的反应不足。
2. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. [J] . Vera-Llonch M, Massarotti E, Wolfe F, Rheumatology . 2008,第4期

机译：阿巴西普在中度至重度活动性类风湿关节炎和对甲氨蝶呤反应不足的患者中的成本效益。
3. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial [J] . Peter C. Taylor, Didier Saurigny, Jiri Vencovsky, Arthritis research & therapy. . 2019,第1期

机译：抗风湿性关节炎（RA）患者对甲氨蝶呤背景疗法的反应不足，对抗氨甲蝶呤疗法的反应不足或不耐受的类风湿性关节炎（RA）患者抗粒细胞巨噬细胞集落刺激因子（GM-CSF）配体的人类单克隆抗体那米单抗的疗效和安全性-TNF（肿瘤坏死因子）生物疗法：一项随机对照试验
4. No adverse physiological responses to infrared whole body hyperthermia in patients with rheumatoid arthritis and ankylosing spondylitis compared to healthy subjects. [C] . F.G.J. OOSTERVELD, E. KOOPMAN, J. OLDE SCHOLTENHUIS, Advances in biomedical research . 2010

机译：与健康受试者相比，类风湿性关节炎和强直性脊柱炎患者对红外全身热疗没有不利的生理反应。
5. Affective Responses to Laboratory Stressors in Rheumatoid Arthritis Patients A Comparison of Mindfulness-based Emotion Regulation and Cognitive Behavioral Interventions. [D] . Arewasikporn, Anne. 2012

机译：类风湿关节炎患者对实验室应激源的情感反应基于正念的情绪调节和认知行为干预的比较。
6. Efficacy and safety of namilumab a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized controlled trial [O] . Peter C. Taylor, Didier Saurigny, Jiri Vencovsky, 2019

机译：抗风湿性关节炎（RA）患者对甲氨蝶呤背景疗法的反应不足对抗氨甲蝶呤疗法的反应不足或不耐受的类风湿关节炎患者（RA）的抗粒细胞巨噬细胞集落刺激因子（GM-CSF）配体的人类单克隆抗体那米单抗的功效和安全性-TNF（肿瘤坏死因子）生物疗法：一项随机对照试验
7. PMS29 CANADIAN COST-EFFECTIVENESS ANALYSIS OF ABATACEPT (ORENCIA™) FOR THE MANAGEMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE [O] . Zou D, Desjardins O, Tsao N, 2010

机译：PMS29 ABATACEPT（ORENCIA™）用于治疗对甲氨蝶呤反应不佳的中度至重度活动性类风湿关节炎的成本效益分析

PMS9 COST-EFFECTIVENESS OF ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)AND INADEQUATE RESPONSE TO METHOTREXATE (MTX) ORTUMOR NECROSIS FACTOR-ALPHA INHIBITORS (ANTI-TNFS):A CANADIAN PERSPECTIVE

著录项

引文网络

相似文献

相关主题

期刊订阅